Pliant Stock Moves Higher On Positive Data From Pulmonary Fibrosis Trial
Pliant Therapeutics Inc (NASDAQ:PLRX) stock is moving higher during the premarket session in reaction to interim results from a Phase 2a…
Pliant Therapeutics Interim Results From Phase 2a PET Imaging Clinical Trial In Patients With Idiopathic Pulmonary Fibrosis; Says ‘Single dose administration of PLN-74809 achieved αvβ6 target engagement up to 98% in the lungs of IPF patients’
- Single dose administration of PLN-74809 achieved αvβ6 target engagement up to 98% in the lungs of IPF patients
- All doses achieved target engagement above the threshold for predicted- Single dose administration of PLN-74809 achieved αvβ6 target engagement up to 98% in the lungs of IPF patients
The Week Ahead In Biotech (Sept. 5-11): Focus On Conferences and Clinical Readouts In Another Quiet Week
Biotech stocks extended their gains in the week ending Sept. 3, partly aided by the broader market strength. The news flow was fairly light ahead of the Labor Day holiday weekend.
Pliant Therapeutics Announces Webcast to Present Interim Clinical Data from Ongoing Phase 2a PET Trial of PLN-74809 in Patients with Idiopathic Pulmonary Fibrosis
Pliant Therapeutics, Inc. (NASDAQ:PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, today announced that the Company plans to issue a
Stocks That Hit 52-Week Lows On Friday
On Friday morning, 155 companies achieved new lows for the year.
The Daily Biotech Pulse: J&J Announces CEO Transition, FibroGen’s Roxadustat Approved In Europe, GeoVax, Sorrento Announce COVID-19 Vaccine Data
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 19)
Pliant Therapeutics Q2 EPS $(0.64) Up From $(1.39) YoY, Sales $1.79M Down From $3.60M YoY
Pliant Therapeutics (NASDAQ:PLRX) reported quarterly losses of $(0.64) per share. This is a 53.96 percent increase over losses of $(1.39) per share from the same period last year. The company reported $1.79 million in